| Autor: |
Giugliano, R.P, Llevadot, J, Wilcox, R.G, Gurfinkel, E.P, McCabe, C.H, Charlesworth, A, Thompson, S.L, Antman, E.M, Braunwald for the In TIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators, E |
| Zdroj: |
European Heart Journal; 2001, Vol. 22 Issue 18, p1702-1715, 14p |
| Abstrakt: |
Aims We examined the geographic variations in InTIME-II, a randomized double-blind trial comparing alteplase with lanoteplase for myocardial infarction.Methods and Results We compared baseline characteristics, management, and outcomes in four regions (Western Europe, Eastern Europe, North America, and Latin America) and in countries with historically different management approaches (Germany vs the U.K., the U.S. vs Canada). Thirty-day mortality in Western Europe, Eastern Europe, North America and Latin America was 6·7%, 7·3%, 5·7%, 10·1%, P<0·0001. Adjusted mortality for Europe was intermediate between North America and Latin America (odds ratios (OR) [95% confidence intervals (CI)] compared to Western Europe: North America 0·84 [0·67–1·0], Eastern Europe 1·2 [1·0–1·4], and Latin America 1·8 [1·3–2·7]). Revascularization rates varied 10-fold but did not explain regional mortality differences. Germany and the U.K. had similar adjusted 1-year mortality (OR for the U.K. 1·16 [0·92–1·5]), although invasive procedures were four- to 10-fold more common in Germany. Similarly the U.S. and Canada had equal adjusted 1-year mortality (OR for Canada 0·85 [0·61–1·17]) despite three-fold higher use of invasive procedures in the U.S.Conclusions Significant geographic variations in practice and adjusted mortality following fibrinolysis persist despite recent guidelines. These findings have important implications in the design and interpretation of international studies, identify under- and over-utilized therapies, and support further study of treatments with marked worldwide variations. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
